• Juvenescence AI is focused on developing drugs that were discovered by Artificial Intelligence Techniques.
  • The Juvenescence AI team will rethink clinical development, working with AI tools to help connect the right patients to the right drug.

Welcome to Juvenescence.AI

About

Juvenescence AI Limited is a drug development and artificial intelligence (AI) company focused on ageing and age-related diseases.
Juvenescence AI works along and provides its partners with operational support. We combine advances in state-of-the-art technologies, such as AI, with classical development expertise in order to prioritise and progress compounds from Insilico Medicine Inc’s end, to automate our drug discovery pipeline through to the clinical proof of concept.

The Company was founded in July 2017 as a subsidiary of Juvenescence Limited, with the mission to find diagnostic and therapeutic agents to address ageing, as well as age-related diseases.

Juvenescence AI Limited is a drug development and artificial intelligence company focussed on ageing and age-related diseases. Juvenescence AI combines advances in artificial intelligence with classical development expertise in order to prioritise and develop compounds from Insilico Medicine, Inc’s end-to-end automated drug discovery pipeline through to clinical proof of concept.

Biographies

Gregory Bailey, M.D

Chief Executive Officer

Gregory Bailey is chairman of Portage Biotech, Inc. a publicly traded drug development company and was previously managing partner of Palantir Group, Inc., a merchant bank specialising in biotech and intellectual property. He has over 15 years of experience in investment banking and has founded several companies. Along with comprehensive experience in healthcare, finance and medicine, Greg brings an extensive involvement in corporate governance. He has co-founded and served on multiple public and private company boards of directors, such as Palantir Group, Inc., Ascent Healthcare Solutions, VirnetX Inc. (VHC:AMEX), Portage Biotech Inc. (PTGEF: OTCBB), DuraMedic Inc., and MediqVentures Ltd. As well, he was the initial financier and an independent director of Medivation, Inc. (MDVN:NASDAQ), recently acquired by the pharmaceutical Pfizer.

Dr. Bailey holds a medical degree from the University of Western Ontario, and practiced Emergency Medicine for ten years before entering finance. He also served as the Managing Director and co-Head of Life Sciences at MDB Capital Group LLC.

Jim Mellon

Chairman

Jim Mellon is a British entrepreneur, philanthropist and investor with interests in several industries. He studied PPE at Oxford University and then began his investment career in Asia and the US, where he worked for two fund management companies, GT Management and Thornton & Co. He established his own business in 1991, which today has two components: a listed fund management company, Charlemagne Capital Limited and an Asian investment group, Regent Pacific Group Limited.

In addition, Jim is a controlling shareholder and a director of Manx Financial Group, an Isle of Man based bank, and a controlling shareholder of Webis Holdings plc. He is also a co-founder of Uramin and Red Dragon Resources, both mining groups. Furthermore, his private company Burnbrae Group is a substantial landlord in Germany and in the Isle of Man, owning outright the hotel chain Sleepwell Hotels Limited, as well as major shareholdings in private and public companies in sectors such as banking, commodities, leisure and healthcare. 

Jim has published four best-selling investment books to date, the three latest being focused on investment opportunities in the life sciences sector. He is also an Honorary Fellow of Oriel College, at the University of Oxford and is a trustee of the Biogerontology Research Foundation, as well as of the Lifeboat Foundation .

Alexander Zhavoronkov, PhD

Principal

Alexander Zhavoronkov, PhD, is the Chief Executive Officer of Insilico Medicine, Inc, a Baltimore-based company applying the latest advances in artificial intelligence to drug discovery, biomarker development, and ageing research. Alexander is the Chief Scientific Officer of the Biogerontology Research Foundation, a UK-based registered charity supporting ageing research worldwide. He is also the director of the International Aging Research Portfolio (IARP) knowledge management project, chief scientist of Youth Laboratories and the adjunct professor of the Moscow Institute of Physics and Technology. He holds two Bachelor Degrees from Queen’ s University, a Masters in Biotechnology from Johns Hopkins University, and a PhD in Biophysics from the Moscow State University. 

Alex Zhavoronkov is the author of over 90 research publications in the peer-reviewed journals and books including "The Ageless Generation: How advances in biomedicine will transform the global economy" (Palgrave Macmillan, 2013) and “Dating AI: A Guide to Falling in Love with Artificial Intelligence” (RE/Search, 2012). Prior to switching his focus to ageing research in 2004, he worked as the director of ATI Technologies, a major Canadian GPU company and was the co-founder of and CSO of NeuroG, a neuroinformatics company. He is the editor of numerous journals including Ageing and Oncotarget: Gerotarget, associate editor of Frontiers in Genetics, and review editor of Frontiers in Molecular Biosciences. He also is co-organizing the annual Aging Research for Drug Discovery Forum and the annual Artificial Intelligence & Blockchain for Healthcare Forum in Basel, Switzerland as part of EMBO/Basel Life congress.

Contact

Juvenescence AI is a drug development firm focused on advancing assets licensed from Insilico Medicine, Inc. Those interested in contacting Juvenescence AI should use the form below.